---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-002116"
form_type: "8-K"
ticker: null
cik: "0001261249"
company_name: "AGILE THERAPEUTICS INC"
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:14:39.031258+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Agile Therapeutics restates 2021-2022 financials; net loss overstated by $3.8M and $23.7M

## Summary
- Audit committee concluded warrants issued in 2021-2022 were improperly classified as equity; should be liabilities at fair value.
- Net loss overstated by $3.8M for FY2021 and $23.7M for nine months ended Sep 30, 2022; no impact on revenue, cash, or operating expenses.
- Company expects to report at least one material weakness in internal controls; financial statements for those periods should no longer be relied upon.
- Nasdaq granted 180-day extension until Aug 14, 2023 to regain minimum $1.00 bid price; shares continue trading on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001558370-23-002116
- form_type: 8-K
- cik: 0001261249
- company_name: AGILE THERAPEUTICS INC
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 4.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1261249/000155837023002116/0001558370-23-002116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1261249/000155837023002116/agrx-20230223x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-002116
- JSON: https://secwatch.observer/filing/0001558370-23-002116.json
- Plain text: https://secwatch.observer/filing/0001558370-23-002116.txt

## Key facts
- Auditor Changes
  AGILE THERAPEUTICS INC reported that prior financial statements should not be relied upon.
  - Action: non reliance
  source text: the audited and unaudited financial statements for each of the Non-Reliance Periods should no longer be relied on.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1261249/000155837023002116/0001558370-23-002116-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.